Summary This chapter contains sections titled: Introduction Pathology of Multiple Myeloma Epidemiology, Aetiology, Genetics and Incidence Signs and Symptoms Investigations Diagnosis Staging of Multiple Myeloma Treatment and Nursing Care in Multiple Myeloma Treatment Nursing Care Conclusion References...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Multiple myeloma is the uncontrolled, malignant proliferation of plasma cells in the bone marrow. In nearly all instances the cells form a single clone, but occasionally the malignant process may have started from two or more cells, and a few patients have been observed in whom a new clone de...
Multiple myeloma (MM) belongs to a group of monoclonal B cell malignancies affecting mainly the elderly, more males than females and causing symptoms both directly by way of tumor mass effects and indirectly by secretion of a variety of cytokines by both tumor and normal cells in response to ...
Pathophysiology Multiple myeloma (MM) is thought to develop from the malignant transformation of post- germinal center plasma cells. Multiple genetic and environmental changes lead to the transformation of these progenitor cells into a malignant neoplasm.3 It appears that the majority of cases of MM ...
C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 42, 1564–1573 (2006). Article CAS PubMed Google Scholar Freund, G. G., Kulas, D. T. & ...
Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic background. Recently, studies aimed at explaining this phenomenon have begun...
The 7 major multiple myeloma markets are expected to exhibit a CAGR of 8% during 2024-2034. This report also provides a detailed analysis of the current multiple myeloma marketed drugs and late-stage pipeline drugs.
Multiple myeloma (MM) is a currently incurable malignancy of plasma cells. Malignant myeloma cells (MMCs) are heavily dependent upon the bone marrow (BM) microenvironment for their survival. One component of this tumor microenvironment, B-Cell Activating
Lipid reprogramming is emerging among the metabolic hallmarks of cancer, and can be also exploited by myeloma PCs to meet the requirements for survival, proliferation, chemoresistance and immune evasion. It has now become clear that the BMM can contribute to the metabolic rewiring of the MM cells...